IL22RA1 and colitis: Despite similar body weights between PBS-treated (control) and hemopexin-treated Il22ra1-/- mice during the experiment (Figure 3B), colitis severity was significantly attenuated by exogenous hemopexin treatment as indicated by lower DAI scores (Figure 3C) and improved colonic lengths when compared to PBS treatment (Figure 3D).